Search En menu en ClientConnect
Top 5 search results See all results Advanced search
Top searches
Most visited pages
    Reference: 20170093
    Release date: 4 April 2017

    Promoter – Financial Intermediary




    Financing the promoter's R&D programme for new plasma proteins for various therapeutic areas, including Alzheimer's disease, liver cirrhosis, diabetes and cystic fibrosis.


    The project covers all stages of development i.e. pre-clinical development as well as clinical development of new health treatments. The project will be managed from the company's headquarters in Barcelona, Spain.


    Proposed EIB finance (Approximate amount)

    EUR 170 million

    Total cost (Approximate amount)

    EUR 502 million

    Environmental aspects

    The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.


    The promoter is a private company not operating in the Utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.


    Signed - 5/12/2017


    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Related tags

    Spain Industry